RxDoctor Payments Data

Phillip Ehlers, MD

Family Medicine · Baton Rouge, LANPI 1902936925

Payments from drug & device makers

$3,017in general payments, 2019–2025

Across 182 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$584
  • Amarin Pharma, Inc.$491
  • Lilly USA, LLC$252
  • Takeda Pharmaceuticals U.S.A., Inc.$247
  • Boehringer Ingelheim$205
  • Pfizer$173
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$2,99499%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,017 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$19,104
Medicare patients
88
Services billed
226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide108$143,006
EliquisApixaban51$66,847
JardianceEmpagliflozin53$63,435
TrulicityDulaglutide29$38,182
TradjentaLinagliptin18$29,067
VascepaIcosapent Ethyl28$27,581
MyrbetriqMirabegron23$24,317
JanumetSitagliptin Phos/Metformin Hcl30$23,478
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$22,893
Janumet XrSitagliptin Phos/Metformin Hcl17$22,170
LinzessLinaclotide21$21,275
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$19,427
Tresiba Flextouch U-200Insulin Degludec20$18,999
OzempicSemaglutide14$18,899
SynjardyEmpagliflozin/Metformin Hcl18$17,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$252$181,187137 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy$205$109,72489 claims
PfizerEliquis$173$66,84751 claims
MerckJanumet, Janumet Xr$126$45,64847 claims
GSKTrelegy Ellipta, Breo Ellipta$130$32,52233 claims
Astellas Pharma US IncMyrbetriq$106$24,31723 claims
AbbVieLinzess, Synthroid$13$22,45647 claims
Novo NordiskOzempic$584$18,89914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →